Gainers
- Quotient QTNT stock rose 35.8% to $0.33 during Wednesday's after-market session. This security traded at a volume of 1.0 million shares come close, making up 143.5% of its average volume over the last 100 days. The company's market cap stands at $1.1 million.
- Baudax Bio BXRX shares moved upwards by 14.34% to $2.63. The market value of their outstanding shares is at $1.4 million.
- OncoCyte OCX stock increased by 12.66% to $0.34. The market value of their outstanding shares is at $40.1 million.
- Lucira Health LHDX shares moved upwards by 12.0% to $0.14. The company's market cap stands at $5.6 million.
- Sharecare SHCR stock rose 11.46% to $1.75. The company's market cap stands at $618.6 million.
- Ensysce Biosciences ENSC shares rose 10.38% to $0.68. The company's market cap stands at $4.3 million.
Losers
- Chembio Diagnostics CEMI stock fell 14.3% to $0.18 during Wednesday's after-market session. The company's market cap stands at $6.6 million.
- Rubius Therapeutics RUBY stock decreased by 13.51% to $0.21. At the close, Rubius Therapeutics's trading volume reached 70.3K shares. This is 9.9% of its average volume over the last 100 days. The company's market cap stands at $18.6 million.
- TransCode Therapeutics RNAZ stock decreased by 11.48% to $0.54. At the close, TransCode Therapeutics's trading volume reached 92.8K shares. This is 3.0% of its average volume over the last 100 days. The company's market cap stands at $7.0 million.
- Minerva Surgical UTRS shares decreased by 8.52% to $0.25. At the close, Minerva Surgical's trading volume reached 9.0 million shares. This is 3802.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.1 million.
- bioAffinity Technologies BIAF shares declined by 6.4% to $1.61. The company's market cap stands at $13.4 million.
- Pasithea Therapeutics KTTA shares declined by 6.09% to $0.54. The market value of their outstanding shares is at $15.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in